Drug patents …
… from Kazakhstan to Kalamazoo
Proactively manage your pharmacy inventory
Anticipate generic drug launch
Manage your formulary budget
Find generic entry opportunities
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
|Title:||Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor|
|Abstract:||In accordance with the present invention, there are provided compositions for the in vivo delivery of substantially water insoluble pharmacologically active agents (such as the anticancer drug taxol) in which the pharmacologically active agent is delivered in a soluble form or in the form of suspended particles. In particular, the soluble form may comprise a solution of pharmacologically active agent in a biocompatible dispersing agent contained within a protein walled shell. Alternatively, the protein walled shell may contain particles of taxol. In another aspect, the suspended form comprises particles of pharmacologically active agent in a biocompatible aqueous liquid.|
|Inventor(s):||Desai; Neil P. (Los Angeles, CA), Soon-Shiong; Patrick (Los Angeles, CA), Sandford; Paul A. (Los Angeles, CA), Grinstaff; Mark W. (Pasadena, CA), Suslick; Kenneth S. (Champaign, IL)|
|Assignee:||VivoRx Pharmaceuticals, Inc. (Santa Monica, CA)|
Patent Claim Types:|
see list of patent claims
|Composition; Delivery; Formulation; Use;|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.